| Item Type | Name |
|
Concept
|
Cell Division
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
G2 Phase
|
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Academic Article
|
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
|
|
Academic Article
|
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Metastatic bladder cancer: advances in treatment.
|
|
Academic Article
|
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
|
|
Academic Article
|
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
|
|
Academic Article
|
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
|
|
Academic Article
|
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
|
|
Academic Article
|
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
|
|
Academic Article
|
A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Angiogenesis inhibitors.
|
|
Academic Article
|
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
|
Academic Article
|
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
|
|
Academic Article
|
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
|
Academic Article
|
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Development of growth inhibitory agents in urological and other malignancies.
|
|
Academic Article
|
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
|
Academic Article
|
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
|
|
Academic Article
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
|
Academic Article
|
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
|
|
Academic Article
|
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
|
|
Academic Article
|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
|
|
Academic Article
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
|
Academic Article
|
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
|
|
Academic Article
|
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
|
|
Academic Article
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
|
|
Academic Article
|
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
|
|
Academic Article
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
|
Academic Article
|
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
|
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
|
Academic Article
|
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
|
|
Academic Article
|
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
|
|
Academic Article
|
Developing drugs that do not cause tumor regression.
|
|
Academic Article
|
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
|
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
|
|
Academic Article
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
|
Academic Article
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
|
Academic Article
|
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
|
|
Academic Article
|
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
|
|
Academic Article
|
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
|
|
Academic Article
|
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
|
|
Academic Article
|
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
|
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
|
Academic Article
|
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
|
|
Academic Article
|
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells.
|
|
Academic Article
|
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
|
Academic Article
|
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
|
|
Academic Article
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
|
Academic Article
|
A phase II study of depsipeptide in refractory metastatic renal cell cancer.
|
|
Academic Article
|
Other paradigms: randomized discontinuation trial design.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
|
|
Academic Article
|
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
|
|
Academic Article
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
|
Academic Article
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
|
Academic Article
|
MR imaging-guided focal laser ablation for prostate cancer: phase I trial.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
|
|
Academic Article
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Predictive markers in advanced renal cell carcinoma.
|
|
Academic Article
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
|
Academic Article
|
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder.
|
|
Academic Article
|
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
|
|
Academic Article
|
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
|
|
Academic Article
|
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
|
|
Academic Article
|
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
|
|
Academic Article
|
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
|
|
Academic Article
|
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
|
|
Academic Article
|
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
|
|
Academic Article
|
A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM).
|
|
Academic Article
|
A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC).
|
|
Academic Article
|
Phase II trial of adjuvant gemcitabine plus cisplatin (GC) with amifostine cytoprotection in patients (pts) with locally advanced bladder cancer (BC).
|
|
Academic Article
|
Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).
|
|
Academic Article
|
Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium.
|
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC).
|
|
Academic Article
|
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
|
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
|
|
Academic Article
|
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
|
|
Academic Article
|
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
|
|
Academic Article
|
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|
|
Academic Article
|
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|
|
Academic Article
|
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
|